Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment

Multiple Sclerosis Journal

Volumn 17, Issue 8, 2011, Pages 958-963

  Hellwig, Kerstin ^a   Haghikia, Aiden ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

natalizumab; pregnancy outcome; relapse; safety

Indexed keywords

NATALIZUMAB;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY TERMINATION; SPONTANEOUS ABORTION;

EID: 80052007513     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511401944     Document Type: Article

References (18)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Haghikia A, Fischer M, Hellwig K, et al. Open use of natalizumab. Neutralising antibodies and clinical data. Nervenarzt. 2008 ; 79: 716-719
3. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008 ; 255: 1449-1463
4. Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 98-107
5. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 6: 117-130
6. Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009 ; 86: 108-116
7. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005 ; 65: 802-806 (Pubitemid 41362118)
8. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010 ; 257: 580-583
9. Hellwig K, Brune N, Haghikia A, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008 ; 118: 24-28 (Pubitemid 351809326)
10. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998 ; 339: 285-291 (Pubitemid 28366416)
11. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy In Multiple Sclerosis Group Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004 ; 127: 1353-1360 (Pubitemid 38745513)
12. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 ; 70: 1150-1151 (Pubitemid 351464749)
13. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009 ; 72: 396-401
14. García-Enguídanos A, Calle ME, Valero J, Luna S, Domínguez-Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol. 2002 ; 102: 111-119 (Pubitemid 34272717)
15. Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol. 2008 ; 255: 623-627
16. Newnham JP, Jobe AH. Should we be prescribing repeated courses of antenatal corticosteroids?. Semin Fetal Neonatal Med. 2009 ; 14: 157-163
17. Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009 ; 66: 958-963
18. Christiano L, Bozic C, Kooijmans M. Preliminary evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy registry. Mult Scler. 2010 ; 16: S294 - S294